Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,068 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,062
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis123
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California498
- Maryland198
- Alabama179
- Florida152
- Arizona150
- Massachusetts118
- New York116
- Texas112
- Illinois82
- Colorado81
Recruiting studies6,068 total
- NCT06693830Recruiting
Blood test guided treatment for newly diagnosed DLBCL
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
New York, New YorkAges 18 years+ - NCT06698211Enrolling by invitation
Posaconazole to prevent fungal infection in stem cell transplant patients with gut GVHD
This trial tests if giving the antifungal drug posaconazole as a tablet can prevent serious fungal infections in people who have had a stem cell transplant and develop gut graft-versus-host disease (GVHD), which is a complication where donor cells attack the digestive tract. It may help protect patients who need strong immune-suppressing treatment for GVHD.
TianjinAges 18–75 - NCT06699810RecruitingPhase 4
Understanding Diabetes Recovery After Severe Blood Sugar Crisis
This study looks at how certain people can recover from a dangerous blood-sugar emergency called DKA (diabetic ketoacidosis). Researchers want to understand why some patients improve and how to help them stay healthy long-term.
Atlanta, GeorgiaAges 18 years+ - NCT06694558Recruiting
Monocytes in type 1 diabetes and kidney disease study
This study looks at immune cells (monocytes) in people with type 1 diabetes, with or without early kidney problems. Researchers want to understand how these cells differ between groups. You may be able to join if you have type 1 diabetes and use an insulin pump or injections along with a continuous glucose monitor (CGM).
Cleveland, OhioAges 18–65 - NCT06702293Recruiting
A therapy app to help with itch from skin conditions
This trial tests a mobile app designed to help reduce itching and related symptoms for people with psoriasis, eczema, or chronic hives. If you have moderate to severe itch and can use an English-language app, this study might be for you.
SingaporeAges 16 years+ - NCT06698003RecruitingPhase 2
Mogamulizumab to Prevent Leukemia in HTLV-1 Carriers
This trial tests whether a drug called mogamulizumab can prevent adult T-cell leukemia/lymphoma in people who carry the HTLV-1 virus and have a high viral load. It is for patients who have not yet developed the blood cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06698822RecruitingPhase 2
Tofacitinib cream for early-stage cutaneous T-cell lymphoma
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
Houston, TexasAges 18 years+ - NCT06694363Recruiting
New test to guide treatment for APDS immune disorder
This study uses a new blood test to find and monitor people with APDS, a rare immune disease, who may be helped by the drug leniolisib. It aims to improve how doctors screen and track treatment response.
BordeauxAges 12 years+ - NCT05667506RecruitingPhase 1/Phase 2
Check CNCT19 cell therapy for relapsed childhood ALL
This early-stage trial tests a personalized immune-cell treatment called CNCT19 in children and teens whose leukemia (ALL) has come back or not responded to prior therapy. It may help the immune system recognize and attack leukemia cells that carry CD19.
Hefei, AnhuiAges 3–18 - NCT05939167RecruitingPhase 1/Phase 2
Stem cell treatment study for people with late-stage HIV
This Phase 1/2 study tests whether mesenchymal stem cells can help people with HIV who have lower immune cell counts. You would join a treatment plan and follow study rules closely, while the researchers track safety and early signs of benefit.
BeijingAges 18–65 - NCT06689800Recruiting
Family communication tool for kids getting transplant or cell therapy
This study looks at a family communication tool for children and teens getting stem cell transplants or cellular therapy. It helps families talk about treatment together.
St Louis, MissouriAges 8 years+ - NCT06691464Enrolling by invitation
Using FAPI PET/CT to find lung scarring in non-healing ARDS
This study uses a special PET/CT scan to look for active scar tissue (fibrosis) in the lungs of people who are still very sick with ARDS after 5 days of ventilator support. It may help doctors understand why some lungs don't heal and could guide future treatments.
Groningen, Provincie GroningenAges 20 years+ - NCT06691698Recruiting
CO-OP therapy for teens with mild intellectual disability
This study tests a therapy called CO-OP, which helps teens with mild intellectual disability learn skills to reach their own goals. You'll work with a therapist once a week for 10 weeks, with a parent or adult to support you.
Kristianstad, Skåne CountyAges 13–17 - NCT06688799RecruitingPhase 1/Phase 2
Anti-CD19 CAR T cells for refractory autoimmune diseases
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
Beijing, Beijing MunicipalityAges 3–65 - NCT06687551RecruitingPhase 4
Testing lower doses of JAK inhibitors for rheumatoid arthritis
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
Toulouse, OccitanieAges 18–65 - NCT06691971Recruiting
Testing a device that detects wheezing in asthma attacks
This study is testing a device called AeviceMD that listens for wheezing—a whistling sound when breathing—to help doctors quickly spot asthma attacks. If you or your child is in the emergency room with a sudden asthma flare-up, you may be able to join.
The Bronx, New YorkAges 3 years+ - NCT06683521Recruiting
Understanding the immune system in FPIES
This study looks at how the immune system works in people with Food Protein-Induced Enterocolitis Syndrome (FPIES). It aims to learn more about this condition to improve future diagnosis and treatment.
New York, New YorkAges 1–60 - NCT06688838Enrolling by invitation
JAK inhibitor for Blau syndrome
This trial tests a new oral drug that blocks inflammation in people with Blau syndrome, a rare genetic condition causing joint, eye, and skin problems. The goal is to see if the drug can reduce symptoms and improve quality of life.
Wuhan, HubeiAges Any age - NCT06686329Recruiting
Exercise for blood sugar correction after insulin timing error
This trial looks at whether physical activity can help treat or prevent high blood sugar caused by taking a rapid-acting insulin dose at the wrong time. If you are a young adult with type 1 diabetes and use a Dexcom G7 continuous glucose monitor, this study may help you learn how to use exercise as a tool for managing unexpected blood sugar spikes.
Montreal, QuebecAges 18–24 - NCT06687772RecruitingPhase 2
Preventing brain relapse in high-risk lymphoma with stem cell transplant
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
St Louis, MissouriAges 18–75 - NCT06375733RecruitingPhase 1/Phase 2
GFH009 plus zanubrutinib for relapsed large B-cell lymphoma
This trial tests a new targeted drug (GFH009) combined with another targeted drug (zanubrutinib) for people with diffuse large B-cell lymphoma that has returned or not improved after at least two prior treatments. It aims to see if this combination can shrink tumors and improve outcomes.
NanningAges 18 years+ - NCT06688435RecruitingPhase 1
Immune cell therapy for hard-to-treat myasthenia gravis
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
JinanAges 18–65 - NCT06688331RecruitingPhase 2
Treating early stage 1 type 1 diabetes in children with cell therapy and antibody
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
BialystokAges 3–18 - NCT06682169RecruitingPhase 3
New pill for chronic graft-versus-host disease after other treatments fail
This trial tests a new pill called rovadicitinib for chronic GVHD that has not improved after 2 to 5 other treatments. It compares the new drug to one chosen by your doctor from a list of approved options.
Hefei, AnhuiAges 18–70
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,068 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,217 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.